Alvotech And DKSH Partner On Adalimumab In Asia
After Deals In Canada, Europe And Israel, Alvotech Targets Asia
Executive Summary
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.
You may also be interested in...
Alvotech And DKSH Extend Partnership For Six Biosimilars
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.
Asia Deal Watch: Betta Will Bring Two Agenus Oncology Candidates To Its Market Area
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
Biocon Licenses Seven In Asia To DKSH
Keen to make strides for its growing Small Molecules business, Biocon has signed an agreement with DKSH to bring seven generic formulations to markets in South East Asia.